Diabetes, Healthy
Conditions
Brief summary
This trial is conducted in Europe. The aim of this trial is to investigate the influence of omeprazole on the pharmacokinetics (the exposure of the trial drug in the body) of oral semaglutide in healthy subjects.
Interventions
DRUGsemaglutide
All subjects will be treated for 10 consecutive days including dose escalation, with 5 days on 5 mg oral semaglutide followed by 5 days on 10 mg oral semaglutide.
DRUGOmeprazole
Will be given daily with oral semaglutide.
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female age 18-75 years (both inclusive) at time of signing informed consent * Body mass index of 18.5-29.9 kg/m\^2 (both inclusive) * A good general health based on medical history, physical examination, and results of vital signs, electrocardiogram and laboratory safety tests performed during the screening visit, as judged by the investigator
Exclusion criteria
* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods. Female of child bearing potential must use effective methods of birth control for the duration of the trial and for 5 weeks following last dose. Only highly effective methods of birth control are accepted (i.e., one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices) * History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease * Hypertension (defined as sitting systolic blood pressure above or equal to 140 mmHg and/or diastolic blood pressure above or equal to 90 mmHg). If white-coat hypertension is suspected at the screening visit a repeated measurement is allowed * Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in excess of 400 mL within the 3 months preceding screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the semaglutide plasma concentration time curve | From time 0 to 24 hours after the 10th daily dose |
Secondary
| Measure | Time frame |
|---|---|
| Area under the SNAC plasma concentration time curve | From time 0 to 24 hours after the 10th daily dose |
| Number of hypoglycaemic episodes | From first dosing (Day 1) to completion of the follow-up visit (Day 43 (± 2 days)) |
Countries
Germany
Outcome results
None listed